Viemed Healthcare Earnings Call Highlights Growth and Guidance

Viemed Healthcare (VMD) reported Q3 record revenue of $80.7M, up 12.2% YoY, and net income of $4.6M, up 32% YoY. Management raised revenue guidance and highlighted growth in sleep and maternal health services, but noted softer margins and audit delays. Adjusted EBITDA was $17.1M, up 6% YoY. The company expects sequential growth in Q4.

Original reporting
Published Nov 15, 2026, 1:59 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 15, 2026, 10:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$VMD
Bullish
medium confidence
Mentioned
$VMD
Relevance
4/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$VMDBullishLow
01

Why it matters

Recap reinforces prior earnings narrative; guidance lift is the only new actionable element.

02

Market read

Limited trading relevance due to recap nature; modest upside potential from raised guidance.

03

What to watch

Potential volatility from ventilation patient trends and audit payment timing could pressure near‑term performance.

Relevance 4/10Novelty 2/10Timing: none

Background

Viemed Healthcare reported Q3 results on 2026-11-04; this article summarizes the call and updates guidance.

Company-level read

Ticker impact

$VMDBullishMedium confidence
Context

Q3 earnings call recap with record revenue, raised full-year revenue guidance and capital return details.

Expected impact

likely modest upside as market prices in higher revenue outlook

Evidence & confidence

Guidance lift signals growth but recaps already‑released numbers, so impact is incremental.

Market effects

Durable medical equipment sector may see slight uplift from Viemed's growth narrative.

U.S. healthcare services segment receives modest positive sentiment.

Limited; company is small‑cap with primarily domestic exposure.

Counterpoint

Guidance raise may be offset by softer gross margins and audit‑related payment delays.

Key entities

  • Viemed Healthcare

    U.S. durable medical equipment provider (ticker VMD).

Related articles

$VMDMedAI 8/10

Viemed Healthcare Q3 Earnings Call Highlights

VieMed Healthcare (VMD) reported Q3 operating cash flow of $11.5M and free cash flow of $4M. The company expects Q4 improvements in collections and active ventilator patients. Full-year revenue guidance was raised to $316M-$320M, while adjusted EBITDA was narrowed to $64M-$66M. VieMed had $9.7M in cash and $5.3M in borrowings at Q3's end, with a $1M share buyback and $2M term-loan repayment in October.

$VMDMed

Viemed Healthcare Inc (VMD) (Q3 2026) Earnings Call Highlights: Record Revenue

Viemed Healthcare reported Q3 2026 record revenue of $80M. CEO Casey Boyd discussed state rollout timelines, expecting gradual growth. CFO Trey Fitzgerald addressed sequential growth gaps, seasonal trends, and financial KPIs, targeting EBITDA above 20%. Accounts receivable delays impacted cash flow but are expected to resolve in Q4. Boyd also updated on sales force training, M&A pipeline, and patient education progress.

$VMDMed

VIEMED HEALTHCARE ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS

VIEMED HEALTHCARE, INC. (VMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. VIEMED HEALTHCARE ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS Lafayette, Louisiana (November 4, 2026) Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, an

$VMDMedAI 8/10

Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands

Viemed Healthcare (NASDAQ: VMD) anticipates low-20% revenue growth in 2026, with projected revenue of $317M and EBITDA of $66M. The company's ventilator business averages $1,050 monthly per rental, with an average patient length of 17 months. Viemed has expanded into sleep therapy, maternal health, and other areas, completing three acquisitions in the past three years. The company has no net debt and has repurchased nearly 700,000 shares. Management sees organic growth and strategic acquisitions